Agios Pharmaceuticals, Inc. filings document the regulatory record of a Delaware, Nasdaq-listed commercial-stage biopharmaceutical company focused on rare diseases and hematology. Its 8-K reports furnish operating results, product revenue updates for PYRUKYND® and AQVESME™, business highlights, investor presentations, and Regulation FD disclosures tied to mitapivat commercialization, clinical programs, and regulatory interactions.
Proxy and current-report filings cover annual-meeting proposals, director elections, board-class structure, committee assignments, stockholder voting matters, and compensatory arrangements for directors. Other disclosures address board appointments, pharmacovigilance communications involving PYRUKYND, exhibit filings, and Inline XBRL cover-page data.
AGIOS PHARMACEUTICALS, INC. principal accounting officer Theodore James Washburn Jr. reported multiple equity transactions linked to restricted stock units. On March 1, 2026, he received a grant of 8,452 restricted stock units, each representing a contingent right to one share of common stock, vesting in three equal annual installments beginning March 1, 2027.
On March 2, 2026, restricted stock units granted in 2023, 2024 and 2025 vested, with 2,350, 2,450 and 2,695 units respectively converting into common stock at no cost. To cover tax withholding obligations from these vestings, he sold a total of 2,223 shares of common stock in open-market transactions at $28.96 per share pursuant to durable automatic sale instructions under Rule 10b5‑1. Following these transactions, he held 6,140 common shares directly, including 75 shares acquired through the company’s employee stock purchase plan.
AGIOS PHARMACEUTICALS, INC. executive Krishnan Viswanadhan, Chief Corporate Development & Strategy, reported equity compensation grants rather than market purchases or sales. He received 14,000 restricted stock units, each representing a right to one share of common stock.
The restricted stock units were granted on March 1, 2026 and will vest in three equal annual installments beginning March 1, 2027. He was also granted stock options covering 52,000 shares at a per-share exercise price of $0.00, vesting 25% on March 1, 2027 and the remaining 75% in 36 equal monthly installments thereafter.
AGIO submitted a Form 144 disclosure concerning Common Stock, showing a scheduled vesting of Restricted Stock Units on 03/02/2026 and a prior sale by a named person. The filing lists a past sale of 18,703 shares on 12/30/2025 for $506,664.00.
The filing identifies Brian Goff as the prior seller and records the vesting event as an issuer action on 03/02/2026. Timing and cash‑flow treatment for the 03/02/2026 item are stated as vesting; sale execution details for any future disposition are not included.
AGIO filing notifies a proposed sale of 5,218 shares of common stock in connection with the vesting of restricted stock units, scheduled 03/02/2026. The filing also reports a prior sale of 2,932 shares on 12/30/2025 by James Burns.
AGIO filed a Form 144 reporting a proposed sale of 4,055 shares of common stock, tied to the vesting of restricted stock units on 03/02/2026.
Shares outstanding were 58,592,172 as of 03/02/2026. The filing also lists prior sales of 2,932 shares on 12/30/2025.
Cecilia Jones reports a proposed sale of 5,035 shares of common stock under Rule 144 tied to the vesting of Restricted Stock Units on 03/02/2026. The filing also shows 2,932 shares sold on 12/30/2025 in the prior three months.
Tsveta Milanova submitted a Form 144 notice relating to proposed sales of Common Stock and records a vesting of Restricted Stock Units on 03/02/2026 for 2,868 shares. The filing lists two recent dispositions: 2,932 shares on 12/30/2025 and 2,872 shares on 01/05/2026.
Agios Pharmaceuticals ownership filing reports that Armistice Capital, LLC and Steven Boyd together beneficially own 3,036,000 shares, representing 5.21% of Agios common stock as reported by the issuer.
The filing states the Reporting Persons have shared voting and dispositive power over those shares and that the Master Fund is the direct holder; the Master Fund disclaims beneficial ownership due to its investment management agreement with Armistice Capital.
Agios Pharmaceuticals, Inc. has filed an automatic shelf registration statement on Form S-3 as a well-known seasoned issuer, allowing it to offer debt securities, common stock, preferred stock, warrants and units from time to time after effectiveness. Specific terms for each issuance will be set in separate prospectus supplements.
Agios is a commercial-stage biopharmaceutical company focused on rare disease treatments, with a foundation in hematology. It plans to use any net proceeds primarily for general corporate purposes, including working capital, research and development, clinical and commercialization expenses, potential acquisitions or investments, and possible repayment or refinancing of debt.
Agios Pharmaceuticals is a commercial-stage biopharma focused on rare hematology, built around the PK activator mitapivat, sold as PYRUKYND® for pyruvate kinase deficiency and AQVESME™ for thalassemia. AQVESME™ received FDA approval in December 2025 for anemia in adults with non‑transfusion‑dependent and transfusion‑dependent alpha- or beta‑thalassemia, with a U.S. launch in January 2026 under a REMS requiring intensive liver monitoring.
For the year ended December 31, 2025, Agios reported a net loss of $412.8 million, compared with net income of $673.7 million in 2024, when results were boosted by a $905.0 million sale of vorasidenib royalty rights and a $200.0 million milestone payment. As of December 31, 2025, accumulated deficit was $561.7 million, and as of February 6, 2026, there were 58,592,172 common shares outstanding.
The company is advancing a pipeline that includes tebapivat for lower‑risk myelodysplastic syndromes and sickle cell disease, AG‑181 for phenylketonuria, and AG‑236 (licensed from Alnylam) for polycythemia vera, alongside extensive global intellectual property. Key risks center on successful commercialization of PYRUKYND® and AQVESME™, clinical and regulatory outcomes for mitapivat and other candidates, dependence on third‑party manufacturers and partners, competition in rare diseases, and the need for additional capital if existing resources prove insufficient.